Home/Filings/4/0001615774-18-001625
4//SEC Filing

Brennan Peter F 4

Accession 0001615774-18-001625

CIK 0000102198other

Filed

Mar 5, 7:00 PM ET

Accepted

Mar 6, 1:08 PM ET

Size

16.9 KB

Accession

0001615774-18-001625

Insider Transaction Report

Form 4
Period: 2018-02-12
Transactions
  • Exercise/Conversion

    Common Stock

    2018-02-12+4,594,11713,850,181 total
  • Conversion

    Warrant

    2018-02-12$0.60/sh+123,530$74,118123,530 total
    Exercise: $0.60Common Stock (123,530 underlying)
  • Conversion

    Warrant

    2018-02-12$0.60/sh+411,765$247,059535,295 total
    Exercise: $0.60Common Stock (411,765 underlying)
  • Conversion

    Warrant

    2018-02-12$0.13/sh+764,706$99,4121,300,001 total
    Exercise: $0.13Common Stock (764,706 underlying)
  • Conversion

    Warrant

    2018-02-12$0.13/sh+1,882,362$244,7073,182,353 total
    Exercise: $0.13Common Stock (1,882,362 underlying)
  • Conversion

    Warrant

    2018-02-12$0.13/sh+1,411,765$176,4714,594,117 total
    Exercise: $0.13Common Stock (1,411,765 underlying)
Footnotes (5)
  • [F1]The Reporting Person received a warrant to purchase 123,530 shares of Common Stock on 02/23/2017 inconnection with a Note Purchase Agreement executed on that date. The exercise price was $0.60 per share. The warrant was exercisable immediately and expired in one year-02/23/2018.
  • [F2]The Reporting Person received a warrant to purchase 411,765 shares of Common Stock on 05/16/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.60 per share. The warrant was exercisable immediately and expired in one year-05/16/2018.
  • [F3]The Reporting Person received a warrant to purchase 764,706 shares of Common Stock on 07/24/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.13 per share. The warrant was exercisable immediately and expired in one year - 07/24/2018.
  • [F4]The Reporting Person received a warrant to purchase 1,882,352 shares of Common Stock on 12/29/2017 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.13 per share. The warrant was exercisable immediately and expired in one year-12/29/2018.
  • [F5]The Reporting Person received a warrant to purchase 1,411,765 shares of Common Stock on 02/01/2018 in connection with a Note Purchase Agreement executed on that date. The exercise price was $0.125 per share. The warrant was exercisable immediately and expired in one year- 02/01/2019.

Issuer

CALMARE THERAPEUTICS Inc

CIK 0000102198

Entity typeother

Related Parties

1
  • filerCIK 0001501353

Filing Metadata

Form type
4
Filed
Mar 5, 7:00 PM ET
Accepted
Mar 6, 1:08 PM ET
Size
16.9 KB